Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Rothman

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Journal of Medicinal Chemistry|January 9, 2004
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activityF Ivy Carroll, Li Zhang, S Wayne Mascarella, et al.
Journal of Medicinal Chemistry|March 8, 2002
Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazineLing-Wei Hsin, Christina M Dersch, Michael H Baumann, et al.
European Journal of Pharmacology|November 27, 2012
Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogsNicholas V Cozzi, Simon D Brandt, Paul F Daley, et al.
Plos One|April 6, 2011
Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertensionRichard B Rothman, Jean L Cadet, Christina M Dersch, et al.
Journal of Medicinal Chemistry|September 6, 2002
Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporterThomas Prisinzano, Elisabeth Greiner, Edward M Johnson, et al.
Journal of Medicinal Chemistry|April 4, 2003
Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazineElisabeth Greiner, Thomas Prisinzano, Edward M Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2005
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administrationRichard B Rothman, Bruce E Blough, William L Woolverton, et al.
Journal of Medicinal Chemistry|February 6, 2004
Importance of phenolic address groups in opioid kappa receptor selective antagonistsJames B Thomas, Scott E Fix, Richard B Rothman, et al.
ACS Chemical Neuroscience|September 29, 2012
Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transportersKasper Severinsen, Johan F Kraft, Heidi Koldsø, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2006
Salvinorin A: allosteric interactions at the mu-opioid receptorRichard B Rothman, Daniel L Murphy, Heng Xu, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Journal of Medicinal Chemistry|January 9, 2004
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activityF Ivy Carroll, Li Zhang, S Wayne Mascarella, et al.
Journal of Medicinal Chemistry|March 8, 2002
Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazineLing-Wei Hsin, Christina M Dersch, Michael H Baumann, et al.
European Journal of Pharmacology|November 27, 2012
Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogsNicholas V Cozzi, Simon D Brandt, Paul F Daley, et al.
Plos One|April 6, 2011
Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertensionRichard B Rothman, Jean L Cadet, Christina M Dersch, et al.
Journal of Medicinal Chemistry|September 6, 2002
Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporterThomas Prisinzano, Elisabeth Greiner, Edward M Johnson, et al.
Journal of Medicinal Chemistry|April 4, 2003
Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazineElisabeth Greiner, Thomas Prisinzano, Edward M Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 12, 2005
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administrationRichard B Rothman, Bruce E Blough, William L Woolverton, et al.
Journal of Medicinal Chemistry|February 6, 2004
Importance of phenolic address groups in opioid kappa receptor selective antagonistsJames B Thomas, Scott E Fix, Richard B Rothman, et al.
ACS Chemical Neuroscience|September 29, 2012
Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transportersKasper Severinsen, Johan F Kraft, Heidi Koldsø, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 25, 2006
Salvinorin A: allosteric interactions at the mu-opioid receptorRichard B Rothman, Daniel L Murphy, Heng Xu, et al.
Pageof 16